OnKure Therapeutics (OKUR) to Release Quarterly Earnings on Thursday

OnKure Therapeutics (NASDAQ:OKUR) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($1.08) per share for the quarter.

OnKure Therapeutics (NASDAQ:OKUR) last announced its earnings results on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51). On average, analysts expect OnKure Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR opened at $4.78 on Wednesday. The company has a 50 day moving average of $5.36. OnKure Therapeutics has a 12-month low of $4.45 and a 12-month high of $20.00. The firm has a market capitalization of $64.22 million, a price-to-earnings ratio of -0.39 and a beta of 0.28.

Wall Street Analysts Forecast Growth

OKUR has been the topic of several research analyst reports. Leerink Partnrs raised OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Oppenheimer reduced their target price on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, March 11th. HC Wainwright cut their price objective on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Finally, Leerink Partners assumed coverage on OnKure Therapeutics in a research note on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price objective on the stock. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, OnKure Therapeutics presently has a consensus rating of “Buy” and an average target price of $32.33.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.